Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat
The Often-Missed Corner of Healthcare That Wall Street Is LovingSubmitted by Nathan Reiff. Publication Date: 3/29/2026. 
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to post some of the market's wildest spikes and drops. Investors who want exposure to the healthcare space but are wary of that turbulence may prefer a "picks and shovels" approach, focusing on firms that supply essential equipment and services to the industry rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though some companies in this subindustry rank among the largest in healthcare. Given the host of external factors that could affect the sector in 2026—shifting subsidies, an aging population with growing needs, inflation, the expanding role of AI, and more—core lab equipment names may look especially attractive. Below are several major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths
Navellier Warns: This Could Leapfrog Elon's SpaceX IPO
Elon Musk could take SpaceX public in 2026, at an estimated $1.75 trillion valuation. The IPO would include Elon's AI model, Grok. But according to Louis Navellier, a radical new AI model will launch this year… over 1,000 times more powerful than Elon's. And the company behind it could outperform SpaceX in the process. Click here for full details (including Louis' new pick — free).
Thermo Fisher Scientific (NYSE: TMO), a $182 billion life-sciences solutions, diagnostics, and analytical instruments company, has had a difficult start to 2026. Shares are down more than 15% year-to-date (YTD), and the company recently slipped into TradeSmith's red zone for financial health. Some of that weakness likely reflects tariffs and foreign exchange (FX) volatility, which together shaved more than 100 basis points off margins in 2025. There are, however, several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion was up 7% year-over-year (YOY) and beat analyst estimates by roughly $250 million. Adjusted earnings per share (EPS) also topped expectations at $6.57. That momentum may reflect recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor systems. Thermo Fisher's broad business mix could provide meaningful downside protection against external pressures. Even if 2026 guidance appears modest (revenue is expected to rise 4% to 6%), improvements in EBITDA margin would be a welcome tailwind, and underlying customer demand remains solid. That may explain why, despite the selloff, analysts remain largely bullish: 17 of 19 rate the company a Buy or equivalent, and consensus estimates suggest more than 29% upside potential. Danaher's Business May Be Improving, Even as Guidance Remains ModestDanaher Corp. (NYSE: DHR) shares are down nearly 20% YTD. The instruments, consumables, and reagents firm faces challenges similar to Thermo Fisher's, though its recent results had positive elements. While 2026 guidance calls for modest core revenue growth of 3% to 6% YOY, the latest quarter delivered a top- and bottom-line beat, and the company generated $5.3 billion in free cash flow in 2025. Two bright spots for 2026 are Danaher's bioprocessing business—which is expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand—and diagnostics. Diagnostics should benefit from FDA clearances, and equipment orders have begun to recover after a prolonged weak period, which could help drive sales growth. Analysts are fairly optimistic about DHR, forecasting about 12.3% earnings growth over the next year and roughly 35% potential share-price upside. That sentiment is reflected in ratings: 19 of 22 analysts currently rate DHR a Buy or equivalent. Agilent's Biocare Purchase Could Be a CatalystAgilent Technologies (NYSE: A) trails the companies above based on its latest earnings, which showed tepid 4.4% YOY revenue growth and modest misses on both revenue and EPS versus expectations. Still, Agilent may have a hidden growth driver in its recent acquisition of Biocare Medical, which strengthens its position in cancer diagnostics. Although the Biocare purchase cost nearly $1 billion, it should add a recurring revenue stream in a fast-growing area. Cancer diagnostics can also be a higher-margin business than some of Agilent's existing operations, which may help improve operating margin (24.6% in the most recent quarter). Despite a roughly 17% YTD decline, analysts see about 42% upside for Agilent shares. Wall Street labels the stock a Moderate Buy overall, with 13 of 16 analysts issuing Buy-or-better ratings. |
